Jingwen Lu
Biographic Data
| ID | 9856966 |
|---|---|
| NAME | Jingwen Lu |
| GIVEN NAMES | Jingwen |
| FAMILY NAME | Lu |
| SIGNATURE | LU J |
| AFFILIATIONS | Fudan University |
| ORCID | 0000-0001-7415-4510 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2025 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer
Aims: Alectinib was approved by the US, Europe and China in 2024 as the first adjuvant targeted therapy for ALK+ NSCLC, lowering risk of disease recurrence or death by 76%. Alectinib addresses a critical gap in postoperative adjuvant therapy for ALK+ NSCLC. From Chinese healthcare-system perspective, this study evaluates the impact of introducing alectinib in adjuvant therapy for stage IB (tumor ≥ 4 cm) to IIIA (UICC/AJCC 7th edition) ALK+ NSCLC …
Test fairness of the in-house College English examination for Chinese non-English major undergraduates
Introduction The in-house College English examination is a high-stakes assessment for College English, a compulsory course for most non-English major undergraduates in China. However, the fairness of such examinations has not received due attention. Methods This paper employs Kunnan’s Test Fairness Framework to investigate common issues of test fairness related to the in-house College English examination, using a university in East China as an ex…
No prominent works on this page.
Test fairness of the in-house College English examination for Chinese non-English major undergraduates
Introduction The in-house College English examination is a high-stakes assessment for College English, a compulsory course for most non-English major undergraduates in China. However, the fairness of such examinations has not received due attention. Methods This paper employs Kunnan’s Test Fairness Framework to investigate common issues of test fairness related to the in-house College English examination, using a university in East China as an ex…
The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer
Aims: Alectinib was approved by the US, Europe and China in 2024 as the first adjuvant targeted therapy for ALK+ NSCLC, lowering risk of disease recurrence or death by 76%. Alectinib addresses a critical gap in postoperative adjuvant therapy for ALK+ NSCLC. From Chinese healthcare-system perspective, this study evaluates the impact of introducing alectinib in adjuvant therapy for stage IB (tumor ≥ 4 cm) to IIIA (UICC/AJCC 7th edition) ALK+ NSCLC …
Adjuvant (1 work) · Adjuvant therapy (1 work) · Alectinib (1 work) · College English (1 work) · Computer Science (1 work) · Educational Research and Pedagogy (1 work) · Global Educational Reforms and Inequalities (1 work) · Lung cancer (1 work) · Lung Cancer Diagnosis and Treatment (1 work) · Lung Cancer Research Studies (1 work)